Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 Effects in humans  




2 Chemistry  




3 Legal status  


3.1  Denmark  




3.2  France  




3.3  Finland  




3.4  Latvia  




3.5  Sweden  




3.6  Switzerland  




3.7  United Kingdom  




3.8  United States  






4 See also  




5 References  




6 Further reading  




7 External links  













AL-LAD






●Deutsch
 ●Polski
 ●Русский
 ●Српски / srpski
 ●Srpskohrvatski / српскохрватски
 ●Suomi
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

AL-LAD
Legal status
Legal status
  • AU: Unscheduled
  • CA: Unscheduled.
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
  • US: Unscheduled, could be illegal if is sold for human consumption under the Federal Analogue Act.
  • Illegal in Denmark and France, could be illegal in many countries if is sold for human consumption or under the several analogue acts[1] Sweden and Switzerland
    • Identifiers

    • (6aR,9R)-N,N-diethyl-7-prop-2-enyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide

    CAS Number
    PubChem CID
    ChemSpider
    UNII
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC22H27N3O
    Molar mass349.478 g·mol−1
    3D model (JSmol)

    • [H][C@@]12Cc3c[nH]c4cccc(C1=C[C@@H](C(=O)N(CC)CC)CN2CC=C)c34

    • InChI=1S/C22H27N3O/c1-4-10-25-14-16(22(26)24(5-2)6-3)11-18-17-8-7-9-19-21(17)15(13-23-19)12-20(18)25/h4,7-9,11,13,16,20,23H,1,5-6,10,12,14H2,2-3H3/t16-,20-/m1/s1 checkY

    • Key:JCQLEPDZFXGHHQ-OXQOHEQNSA-N checkY

     ☒NcheckY (what is this?)  (verify)

    AL-LAD, also known as 6-allyl-6-nor-LSD, is a psychedelic drug and an analogoflysergic acid diethylamide (LSD).[2] It is described by Alexander Shulgin in the book TiHKAL (Tryptamines i Have Known And Loved). It is synthesized starting from nor-LSD as a precursor, using allyl bromide as a reactant.

    Effects in humans[edit]

    AL-LAD on blotter paper

    While AL-LAD has subtly different effects than LSD, and appears to be slightly shorter lasting, their potencies are similar;[3][4] an active dose of AL-LAD is reported to be between 50 and 150 micrograms.[5] AL-LAD has a known but short and highly uncommon history of recreational human use, which originated in Ireland and the UK, but spread internationally.[citation needed]

    Chemistry[edit]

    AL-LAD does not cause a color change with the Marquis, MeckeorMandelin reagents,[6] but does cause the Ehrlich's reagent to turn purple because of the presence of the indole moiety in its structure.

    Legal status[edit]

    AL-LAD is not scheduled by the United Nations' Convention on Psychotropic Substances.[7]

    Denmark[edit]

    AL-LAD is illegal in Denmark.[8]

    France[edit]

    AL-LAD is illegal in France.[9]

    Finland[edit]

    Listed in a decree of the government's psychoactive substances banned from the consumer market.[10][11]

    Latvia[edit]

    AL-LAD is possibly illegal in Latvia. Although it isn't specifically scheduled, it may be controlled as an LSD structural analog due to an amendment made on June 1, 2015.[12]

    Sweden[edit]

    The Riksdag added AL-LAD to Narcotic Drugs Punishments Act under Swedish schedule I ("substances, plant materials and fungi which normally do not have medical use" ) as of January 26, 2016, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:35 listed as 6-allyl-6-nor-LSD, AL-LAD, and 6-allyl-N,N-dietyl-9,10-didehydroergolin-8-karboxamid.[13]

    Switzerland[edit]

    AL-LAD is illegal in Switzerland.[14]

    United Kingdom[edit]

    AL-LAD is illegal in the UK. On June 10, 2014 the UK Advisory Council on the Misuse of Drugs (ACMD) recommended that AL-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying any harm associated with its use.[15] The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.

    United States[edit]

    AL-LAD is a Controlled Substance at the federal level in the United States,[16] AL-LAD is legally considered an analogofLSD, therefore, sales or possession with intent for human consumption could be prosecuted under the Federal Analogue Act.[17]

    See also[edit]

    References[edit]

    1. ^ "Arrêté du 20 mai 2021 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants" [Order of May 20, 2021 amending the order of February 22, 1990 setting the list of substances classified as narcotics]. Journal officiel de la République française [Official Journal of the French Republic (JORF)] (in French). 20 May 2021.
  • ^ Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, et al. (January 2017). "6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)". Drug Testing and Analysis. 9 (1): 38–50. doi:10.1002/dta.1985. PMC 5411264. PMID 27265891.
  • ^ Schifano F, Orsolini L, Papanti D, Corkery J (June 2016). "NPS: Medical Consequences Associated with Their Intake". Current Topics in Behavioral Neurosciences. Vol. 32. Springer International Publishing. pp. 351–380. doi:10.1007/7854_2016_15. ISBN 978-3-319-52442-9. OCLC 643052237. PMID 27272067.
  • ^ Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–5. doi:10.1021/jm00147a022. PMID 4032428.
  • ^ Shulgin A (1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. p. 392. ISBN 978-0-9630096-9-2. Archived from the original on 2015-11-18.
  • ^ Ecstasydata. "AL-LAD (Not sold as ecstasy)". EcstasyData.org. Archived from the original on 2013-12-26. Retrieved 2013-12-25.
  • ^ Rupprich S. "Conventions". www.unodc.org. Archived from the original on 12 January 2018. Retrieved 4 May 2018.
  • ^ "Lists of euphoriant substances". The Danish Medicines Agency. September 2015. Archived from the original on 2016-06-09.
  • ^ "Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants". Republique Française. May 2021.
  • ^ "FINLEX ® - Säädökset alkuperäisinä: Valtioneuvoston asetus kuluttajamarkkinoilta… 166/2016" [FINLEX ® - Legislation in original form: Government Decree on the consumer market... 166/2016]. www.finlex.fi. Retrieved June 11, 2023.
  • ^ "FINLEX ® - Säädökset alkuperäisinä: Valtioneuvoston asetus kuluttajamarkkinoilta… 225/2017". www.finlex.fi (in Finnish). Retrieved June 11, 2023.
  • ^ "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" [Regulations on controlled narcotic substances, psychotropic substances and precursors in Latvia]. LIKUMI.LV. Archived from the original on 4 May 2018. Retrieved 4 May 2018.
  • ^ "Gemensamma författningssamlingen avseende hälso- och sjukvård, socialtjänst, läkemedel, folkhälsa m.m." [Joint constitutional collection on health care, social services, pharmaceuticals, public health, etc.] (PDF). Lakemedelsverket (in Swedish). Archived (PDF) from the original on 2017-10-31. Retrieved 2017-04-21.
  • ^ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" [EDI ordinance on the lists of narcotics, psychotropic substances, precursor substances and auxiliary chemicals] (in German). Der Bundesrat. Archived from the original on 2016-01-23.
  • ^ ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Archived (PDF) from the original on 6 October 2014. Retrieved 10 June 2014.
  • ^ "PART 1308 - Section 1308.11 Schedule I". www.deadiversion.usdoj.gov. Archived from the original on 27 August 2009. Retrieved 4 May 2018.
  • ^ "Erowid Analog Law Vault : Federal Controlled Substance Analogue Act Summary". www.erowid.org. Archived from the original on 17 April 2018. Retrieved 4 May 2018.

    • Further reading[edit]

    • Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB (April 1995). "LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors". Psychopharmacology. 118 (4): 401–9. doi:10.1007/BF02245940. PMID 7568626. S2CID 21484356.
  • Niwaguchi T, Nakahara Y, Ishii H (May 1976). "[Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds]". Yakugaku Zasshi. 96 (5): 673–8. doi:10.1248/yakushi1947.96.5_673. PMID 987200.
  • Pfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE (1994). "Lysergamides revisited" (PDF). Hallucinogens: An Update. NIDA Research Monograph. Vol. 146. United States Department of Health and Human Services. pp. 52–73. PMID 8742794. Archived from the original (PDF) on 2015-07-23.

    • External links[edit]


    Retrieved from "https://en.wikipedia.org/w/index.php?title=AL-LAD&oldid=1220756061"
    Categories: 
    ●Designer drugs
     ●Lysergamides
     ●Serotonin receptor agonists
     ●Allylamines
     Hidden categories: 
    ●CS1 French-language sources (fr)
     ●CS1 Finnish-language sources (fi)
     ●CS1 Swedish-language sources (sv)
     ●CS1 German-language sources (de)
     ●Articles with short description
     ●Short description is different from Wikidata
     ●Drugs with non-standard legal status
     ●Articles with changed CASNo identifier
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Drugs missing an ATC code
     ●Drugboxes which contain changes to verified fields
     ●Drugboxes which contain changes to watched fields
     ●All articles with unsourced statements
     ●Articles with unsourced statements from October 2022
     ●Webarchive template wayback links
      


    ●This page was last edited on 25 April 2024, at 18:44 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki